Clinical Trial Update: Denosumab China Phase III Study [Phase 3]

View source ↗

Summary

Phase III results for denosumab in Chinese postmenopausal osteoporosis patients. The trial has completed and results were posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoporosis
• Postmenopausal Osteoporosis

Drugs mentioned

• Denosumab (denosumab)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Osteoporosis, Postmenopausal | Phase 3 | Status: COMPLETED | Results posted: 2016-10-31